Результаты поиска

Systemic Therapies for Desmoid Tumors: A Review of Past, Present, and Future Treatments.

Desmoid tumors (DTs) are rare, fibroblastic neoplasms characterized by locally aggressive behavior, unpredictable clinical trajectories, and a substantial impact on patient quality of life despite minimal metastatic potential. Although the underlying biology of DTs remains incompletely defined, associations with prior trauma, hormonal exposure, and aberrant Wnt/β-catenin signaling-including somatic CTNNB1 mutations and germline APC alterations seen in Familial Adenomatous Polyposis-have informed both historical and contemporary therapeutic approaches. Management strategies have evolved from su

Совпадение в полном тексте источника
… For example, Hamada et al. reported that the CTNNB1 S45F mutation was associated with poor response to meloxicam, and all S45F-mutant tumors in their prospective cohort demonstrated progressive disease [ 22 ]. … Successful treatment with meloxicam, a cyclooxygenase-2 inhibitor, of patients with extra-abdominal desmoid tumors: A pilot study J. Clin. Oncol. 2010 28 e107 e109 10.1200/JCO.2009.25.5950 20026797 22. Hamada S. Futamura N. Ikuta K. Urakawa H. Kozawa E. Ishiguro N. Nishida Y. …

Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.

OBJECTIVE: To evaluate the incidence and risk profiles for gastrointestinal (GI) events and cardiovascular (CV) events in elderly patients ( … r celecoxib, and 4183 (33.2%) were for etoricoxib. The most common traditional NSAID prescribed was meloxicam (24%), followed by nimesulide (21.4%) and naproxen (13.1%). The mean age of cohort was 69.6 years, with the majority being female (74%). We found a comparable dose of celecoxib (200 mg OD) and etoricoxib (90 mg OD) prescribed in the respective patie …

Marketed nonsteroidal anti-inflammatory agents, antihypertensives, and human immunodeficiency virus protease inhibitors: as-yet-unused weapons of the oncologists' arsenal.

Experimental data indicate that several pharmacological agents that have long been used for the management of various diseases unrelated to cancer exhibit profound in vitro and in vivo anticancer activity. This is of major clinical importance, since it would possibly aid in reassessing the therapeutic use of currently used agents for which clinicians already have experience. Further, this would obviate the time-consuming process required for the development and the approval of novel antineoplastic drugs. Herein, both pre-clinical and clinical data concerning the antineoplastic function of dist

Совпадение в полном тексте источника
… Etodolac and meloxicam also display selectivity toward COX-2, whereas NSAIDs, such as sulindac and ibuprofen, mediate non-selective COX-1/2 blockage. 17 , 18 Currently, the main therapeutic indication of NSAIDs is for the management of different types of acute or chronic pain and inflammation. 16 , 19 … has been shown to trigger apoptosis in both COX-2-dependent and COX-2-independent routes in hepatocellular carcinoma cells. 38 Similarly, meloxicam can act either in a COX-2-dependent or COX-2-independent fashion in osteosarcoma at multiple levels. 39 The chemopreventive role of the coxibs against …

Single dose oral analgesics for acute postoperative pain in adults - an overview of Cochrane reviews.

BACKGROUND: This is an updated version of the original Cochrane overview published in Issue 9, 2011. That overview considered both efficacy … , and oxycodone 5 mg (low quality evidence). No trial data were available in reviews of acemetacin, meloxicam, nabumetone, nefopam, sulindac, tenoxicam, and tiaprofenic acid. Inadequate amounts of data were available for nine drugs and doses, and data potentially susceptible to publication bias for 13 drugs and doses (very low quality evidence). AUTHORS' C …

2018 ACVIM Forum Research Report Program. Seattle, Washington, June 14 - 16, 2018.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Twenty‐four Angus steers were randomly allocated into 4 treatment groups; Meloxicam (MEL, 0.5 mg.kg BW every 48 hours for 3 treatments), Ceftiofur (CEF, Excenel RTU 2.2 mg/kg SQ every 48 hours for 3 treatments), Meloxicam and Ceftiofur (MEL+CEF, each at concordant dosages, routes, and duration), and … In conclusion, meloxicam, when combined with antimicrobials, can improve clinical illness behavior and economically relevant performance outcomes and should be considered an important adjunctive therapy. …

Toxicity of zoledronic acid after intravenous administration: A retrospective study of 95 dogs.

BackgroundThere is a paucity of veterinary literature on the safety or outcome of zoledronic acid (ZA) use in dogs for either bone pain or hypercalcemia.Hypothesis/objectivesThe primary aim was to report the adverse events in dogs receiving intravenous administration of ZA.AnimalsNinety-five dogs with ZA use.MethodsA retrospective cohort study was performed; all dogs that received at least 1 dose of ZA and had a serum biochemistry profile performed before and after treatment were reviewed. Diagnosis, indication for treatment, adverse events and survival times were recorded.ResultsNinety-five d

Совпадение в полном тексте источника
… Dogs that developed vomiting, diarrhea, or both, were concurrently receiving medication with known gastrointestinal adverse effects: carboplatin (n = 2), meloxicam (n = 1), and lomustine (n = 1). The exact cause of the vomiting, diarrhea, or both could therefore not be identified. … The dog received palliative therapy with ZA (0.22 mg/kg) and analgesia including paracetamol and meloxicam. The serum creatinine and urea were 3.82 and 405 mg/dL, respectively, at the time of the fourth administration of ZA. …

Oral chemotherapy agents in cats: clinical uses, administration and side effects.

PRACTICAL RELEVANCE: Cancer is a very common disease in cats, and many feline patients will require chemotherapy as part of their treatment plan, either as a sole agent or as part of multimodality therapy. Although some general practitioners might be reluctant to undertake injectable chemotherapy, oral chemotherapy may feel like a more acceptable treatment option to manage in practice. CLINICAL CHALLENGES: The small body size of many cats means that tablet sizes made for the human market are less appropriate, which creates dosing challenges. The administration of oral medication can also be a

Совпадение в полном тексте источника
… The licensed NSAID meloxicam, most commonly used in cats, is available as a liquid formulation (0.5 mg/ml) ( Figure 9 ). … Low dose meloxicam is safe and tolerable when combined with toceranib phosphate in cancer-bearing cats. J Feline Med Surg 2022; 24: 1187–1194. 89. Kongara K, Chambers JP. Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy, and place in therapy. …

Soluble Biomarkers of Osteoporosis and Osteoarthritis, from Pathway Mapping to Clinical Trials: An Update.

Serum biomarkers of osteoarticular diseases have been in the limelight of current clinical research trends. Laboratory validation of defined and candidate biomarkers for both osteoarthritis and osteoporosis is of key importance for future decisional algorithms in the diagnosis, monitoring, and prognosis of these diseases. The current guidelines recommend the use of collagen degradation remnants, eg, CTX-I and CTX-II, in the complementary diagnosis of both osteoporosis and osteoarthritis. Besides the collagen degradation markers, enzymes that regulate bone and articular metabolism are useful in

Совпадение в полном тексте источника
… Meloxicam ameliorates the cartilage and subchondral bone deterioration in monoiodoacetate-induced rat osteoarthritis. PeerJ . 2017;5:e3185. doi: 10.7717/peerj.3185 70. Kapoor M, Martel-Pelletier J, Lajeunesse D, Pelletier JP, Fahmi H. … Mid-term effects of meloxicam on collagen type II degradation in a rat osteoarthritis model induced by iodoacetate. Farmacia . 2015;63(4):556–560. 92. Luo Y, Bay-Jensen A, Karsdala M, Qvist P, He Y. Serum CTX-II does not measure the same as urinary CTX-II. …

Anaesthesia as an influence in tumour progression.

PURPOSE: Tumour growth and the formation of metastases are essential elements in the progression of cancer. The centre of treatment is the surgical resection of primary solid tumours. But even if the tumour can be removed without microscopic residual cells, local recurrences and distant metastases occur and determine the patient's fate. During the operation, tumour cells are shed from the primary tumour and released into the circulation. These circulating tumour cells might play an important role in the formation of new tumour sites. Therefore, a functional innate and adaptive immune system is

Совпадение в полном тексте источника
… Another randomized study measured the apoptotic rate in squamous cell carcinoma cells of the oesophagus in patients who either received the COX-2 inhibitor meloxicam 2 weeks prior to surgery or not. … They found a significant increase in apoptotic cells in the resected tumour tissue of patients receiving meloxicam (6.2% vs. 1.2%, p = 0.0005) [ 24 ]. …

Osteoarthritis of the knee - biochemical aspect of applied therapies: a review.

The most prevalent form of arthritis is osteoarthritis (OA) of the knee, which is characterized by a degeneration of articular cartilage resulting in the development of osteophytes, or bone spurs. Main goals of OA treatment are to reduce pain, slow the disease progression, and improve joint function and the quality of life. The purpose of this study was to verify all the therapies recommended by the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) from the biochemical point of view. Non-steroidal anti-inflammatory drugs (NSAIDs) inhibit the synthesi

Совпадение в полном тексте источника
… An increased risk of acute myocardial infarction and kidney failure is associated with all NSAIDs, while the risk of a stroke is linked to the diclofenac and meloxicam usage, especially in the group of elderly ( Figure 3 ) [ 30 ]. FIGURE 3 NSAIDs side effects and mechanism of their action. … An increased risk of acute myocardial infarction and kidney failure is associated with all NSAIDs, while the risk of a stroke is associated to the diclofenac and meloxicam usage, especially in the group of elderly. …

Diagnostic benefits of platelet-to-lymphocyte, neutrophil-to-lymphocyte, and albumin-to-globulin ratios in dogs with nasal cavity diseases.

BACKGROUND: A multimodal approach for diagnostic tests under anesthesia is required to diagnose nasal cavity pathology (NP) reliably in dogs. Blood test results may provide clues to the suspected NP. METHODS: This prospective blinded study assessed 72 dogs with chronic nasal discharge due to NPs, and 10 healthy dogs as the control group (CG). NPs were diagnosed using whole-body computed tomography (CT), upper airway endoscopy, examination of nasal mucosal swabs by bacterial and fungal culture, and histopathological examination of nasal mucosa biopsies. The exclusion criteria were the presence

Совпадение в полном тексте источника
… A pilot study described different treatment protocols with meloxicam and/or corticosteroids [ 10 ]. Types of mucosal inflammation found in dogs with IR, including lymphoplasmacytic inflammation, can also be found in dogs with ONDs or nasal FBs [ 3 ]. … The evaluation of three treatment protocols using oral prednisone and oral meloxicam for therapy of canine idiopathic lymphoplasmacytic rhinitis: a pilot study. Ir Vet J. 2018;71:19. doi: 10.1186/s13620-018-0131-3. 11. …

Abstracts from the 8th Drug Hypersensitivity Meeting (DHM)

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… Labeled 1 0.10 Floxacillin Not approved 1 0.10 Streptomycin Not labeled 1 0.10 Sulfadiazine Labeled 1 0.10 NSAIDs US FDA n (%) Diclofenac potassium Labeled 9 0.88 Piroxicam Labeled 8 0.78 Etoricoxib Not approved 7 0.68 Celecoxib Labeled 4 0.39 Mefenamic acid Labeled 4 0.39 Ibuprofen Labeled 3 0.29 Meloxicam … | 0.81 | CEFALEXINE CEFALINE ® | 0.7 | CEFIXIME CLARADOL ® | 0.72 | CYCLADOL DOXYLAMINE ® | 0.72 | DOXYCYCLINE ERYTHROCINE ® | 0.75 | ARTHROCINE IMNOVID ® | 0.74 | INDOCID LAMISIL ® | 0.75 | LAMICTAL LAROXYL ® | 0.78 | CLAMOXYL LECTIL ® | 0.71 | TILCOTIL LIDENE ® | 0.76 | LODINE MELODIA ® | 0.75 | MELOXICAM …

Some Aspects and Convergence of Human and Veterinary Drug Repositioning.

Drug innovation traditionally follows a de novo approach with new molecules through a complex preclinical and clinical pathway. In addition to this strategy, drug repositioning has also become an important complementary approach, which can be shorter, cheaper, and less risky. This review provides an overview of drug innovation in both human and veterinary medicine, with a focus on drug repositioning. The evolution of drug repositioning and the effectiveness of this approach are presented, including the growing role of data science and computational modeling methods in identifying drugs with po

Совпадение в полном тексте источника
… Meloxicam H | Metacam | EMEA/V/C/ 000033 | 7 January 1998 | Central authorization, EMA | Dog | Reduction in inflammation and pain relief in acute and chronic musculoskeletal disorders. … Saito et al. [ 224 ] investigated COX-2 inhibitors (meloxicam, etodolac, celecoxib) in canine mammary tumor cells. All inhibitors suppressed cell growth, and etodolac and celecoxib were particularly effective in inducing apoptosis via the mitochondrial pathway. …

Дело о амеланотической плазмоцитоидной меланоме с сильным CD138, имитируя многократную миелому - доклад о деле.

Фон и объектив Melanomas имеют различные патологические особенности, которые имитируют другие опухоли, такие, как лимфома, саркома и даже слабо различимая карцинома. Самый недавно выявленный вариант — вариант плазмоцитоида — является необычным вариантом, который может выглядеть как одиночная опухоль или метастатическое заболевание. Из-за его редкости эпидемиологический профиль этого варианта не является достаточно точным. Этот случай иллюстрирует диагностический вызов плазмоцитоидного имитатора клеток, который редко встречается в повседневной практике. 49-year-old Человек подавал многочисленны

Совпадение в полном тексте источника
… Other prescriptions were cefixime 1x200 mg, meloxicam 1x15 mg, and ranitidine 2x150 mg orally. However, the patient unfortunately passed away before any follow-up was able to be conducted. …

Bilateral Knee Effusions Secondary to Zoledronic Acid Infusion.

Intravenous zoledronic acid is an established and generally well tolerated form of antiresorptive therapy for osteoporosis. Although mild arthralgias are a well-documented manifestation of the acute phase response to intravenous bisphosphonates, more severe musculoskeletal reactions manifesting as debilitating pain and joint effusions have been rarely documented in the current literature. In this case report, we discuss the case of a 55-year-old woman who developed severe painful bilateral knee effusions within 1 week of her first zoledronic acid infusion for osteoporosis. Prescribing physicia

Совпадение в полном тексте источника
… . | Paracetamol and meloxicam White (2015) [ 7 ] | 81-year-old woman with osteoporosis and multiple other medical comorbidities including ischemic heart disease, hypertension, type 2 diabetes mellitus, atrial fibrillation, and recurrent falls | Developed sudden onset severe arthralgia and swelling of …

Cancer cachexia: mechanisms and clinical implications.

Cachexia is a multifactorial process of skeletal muscle and adipose tissue atrophy resulting in progressive weight loss. It is associated with poor quality of life, poor physical function, and poor prognosis in cancer patients. It involves multiple pathways: procachectic and proinflammatory signals from tumour cells, systemic inflammation in the host, and widespread metabolic changes (increased resting energy expenditure and alterations in metabolism of protein, fat, and carbohydrate). Whether it is primarily driven by the tumour or as a result of the host response to the tumour has yet to be

Совпадение в полном тексте источника
… The COX-2 inhibitor, meloxicam showed activity against PIF-induced proteolysis, prior to its withdrawal from the market [ 120 ]. Beta-adrenoreceptor blockade can reduce resting energy expenditure in patients with cancer ( n = 10) but have not been trialled in larger-scale studies [ 121 ]. … randomised trial of rofecoxib and prolonged constant infusion of gemcitabine in advanced non-small-cell lung cancer: the GEmcitabine-COxib in NSCLC (GECO) study Lancet Oncology 2007 8 6 500 512 17513173 10.1016/S1470-2045(07)70146-8 120 Hussey HJ Tisdale MJ Effect of the specific cyclooxygenase-2 inhibitor meloxicam …

Rare Causes of Musculoskeletal Pain: Thinking beyond Common Rheumatologic Diseases.

OBJECTIVES: Rare metabolic bone diseases can present with symptoms mimicking more common rheumatological conditions including spondyloarthritis, osteoarthritis, and fibromyalgia. Increasing awareness of these rare diseases within the rheumatology community is vital to ensure that affected patients are diagnosed and appropriately treated. The literature includes several reports of tumour-induced osteomalacia initially diagnosed as rheumatic disease, but other rare diseases such as X-linked hypophosphatemia (XLH) and hypophosphatasia (HPP) also deserve attention. Here, we describe two cases of a

Совпадение в полном тексте источника
… He had not responded to meloxicam or adalimumab. Notably, he also had a history of poor dentition and progressive hearing loss. Genetic testing subsequently confirmed a diagnosis of XLH. A third brother with an AS diagnosis has also recently been diagnosed with XLH. 3.2. …

Celecoxib for rheumatoid arthritis.

BACKGROUND: Rheumatoid arthritis is a systemic auto-immune disorder that causes widespread and persistent inflammation of the synovial linin … sSeven studies (N = 2930) compared celecoxib and tNSAIDs (amtolmetin guacyl, diclofenac, ibuprofen, meloxicam, nabumetone, naproxen, pelubiprofen); one study included comparisons of both placebo and tNSAIDs (N = 1149).There was a small improvement, which may not be clinically significant, in numbers of participants achieving ACR20 criteria response in the c …

TGFα контролирует контрольно-пропускные пункты в СНК, проживающих в них, и внедряет иммунные клетки в целях содействия урегулированию проблемы воспаления.

После острых повреждений в центральной нервной системе (КНС) взаимодействие микроглий, астроцитов и проникновение иммунных клеток принимает решение об их разрешении или хронизации. Однако этот перекрестный разговор CNS-интригинальный характерен плохо. Анализируя образцы цереброспайнальной жидкости (CSF) пациентов с множественным склерозом (MS), а также образцы CNS женских мышей с экспериментальным аутоиммунным энцефаломиелитом (EAE), т.е. С помощью механистических исследований in vitro, в парадигмах лечения vivo, последовательности scRNA, моделей генетического возмущения CRISPR-Cas9 и MRI в мо

Совпадение в полном тексте источника
… Subcutaneous injection of Meloxicam (3 mg/kg) were administered every 12 h post i.c.v. injection for a period of 2 days. The mice were given 4–7 days to recover before the induction of EAE. … To minimize discomfort, mice received a subcutaneous injection of 1 mg/kg Meloxicam after the intracerebroventricular (i.c.v.) injection and again 48 h later. Analysis of the mice was performed 7 days post-injection. …

Vertebral giant cell tumour of bone in a domestic shorthair cat.

Case summaryA 10-year-old male neutered domestic shorthair cat was presented with a 5-month history of progressive non-ambulatory paraparesis. Initial vertebral column radiographs revealed an L2-L3 expansile osteolytic lesion. Spinal MRI showed a well-demarcated, compressive expansile extradural mass lesion affecting the caudal lamina, caudal articular processes and right pedicle of the second lumbar vertebra. The mass was hypointense/isointense on T2-weighted images, isointense on T1-weighted images and had mild homogeneous contrast enhancement after gadolinium administration. MRI of the rema

Совпадение в полном тексте источника
… The cat was treated with meloxicam (0.05 mg/kg q24h PO [Loxicom; Norbrook]) and frunevetmab (1 mg/kg SC q28 days [Solensia; Zoetis]) for suspected spinal arthritis, and the cat’s activity level increased initially. Figure 1 (a) Radiograph, (b,c) MRI and (d,e) CT of the lumbar spine of a cat. …